Regeneron Pharmaceuticals (REGN) Competitors

$712.77 -2.12 (-0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$706.38 -6.39 (-0.90%)

As of 07:57 PM Eastern

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), and Vir Biotechnology (VIR). These companies are all part of the "med - biomed/gene" industry.

How does Regeneron Pharmaceuticals compare to Amgen?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Regeneron Pharmaceuticals currently has a consensus price target of $826.59, suggesting a potential upside of 15.97%. Amgen has a consensus price target of $357.12, suggesting a potential upside of 8.35%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.1%. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Amgen	20.96%	137.41%	13.28%

In the previous week, Amgen had 21 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 44 mentions for Amgen and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.11 beat Amgen's score of 0.89 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	16 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	27 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Amgen has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.25	$4.50B	$41.04	17.37
Amgen	$36.75B	4.84	$7.71B	$14.37	22.94

Summary

Regeneron Pharmaceuticals beats Amgen on 10 of the 19 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.25	$4.50B	$41.04	17.37
Gilead Sciences	$29.44B	5.63	$8.51B	$7.34	18.19

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Gilead Sciences had 53 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 76 mentions for Gilead Sciences and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.11 beat Gilead Sciences' score of 0.68 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	16 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Gilead Sciences	32 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	12 Negative mention(s)	4 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals currently has a consensus price target of $826.59, suggesting a potential upside of 15.97%. Gilead Sciences has a consensus price target of $157.04, suggesting a potential upside of 17.61%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.86

Gilead Sciences has a net margin of 30.99% compared to Regeneron Pharmaceuticals' net margin of 29.65%. Gilead Sciences' return on equity of 48.19% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Gilead Sciences	30.99%	48.19%	18.28%

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 15 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Moderna?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.25	$4.50B	$41.04	17.37
Moderna	$1.94B	10.79	-$2.82B	-$8.15	N/A

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 21 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 44 mentions for Moderna and 23 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.11 beat Moderna's score of 0.52 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	16 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	20 Very Positive mention(s)	9 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals currently has a consensus price target of $826.59, suggesting a potential upside of 15.97%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 32.43%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Moderna's net margin of -143.55%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Regeneron Pharmaceuticals beats Moderna on 13 of the 17 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.25	$4.50B	$41.04	17.37
Intellia Therapeutics	$67.67M	25.67	-$412.69M	-$3.83	N/A

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 15 more articles in the media than Intellia Therapeutics. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 8 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 1.11 beat Intellia Therapeutics' score of 0.87 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	16 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Intellia Therapeutics' net margin of -609.85%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Intellia Therapeutics	-609.85%	-56.81%	-45.34%

Regeneron Pharmaceuticals currently has a consensus price target of $826.59, suggesting a potential upside of 15.97%. Intellia Therapeutics has a consensus price target of $20.55, suggesting a potential upside of 42.48%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Intellia Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 16.0% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Regeneron Pharmaceuticals had 7 more articles in the media than Vir Biotechnology. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 16 mentions for Vir Biotechnology. Regeneron Pharmaceuticals' average media sentiment score of 1.11 beat Vir Biotechnology's score of 0.03 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	16 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Vir Biotechnology's net margin of -638.88%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.25	$4.50B	$41.04	17.37
Vir Biotechnology	$64.69M	23.16	-$437.99M	-$3.13	N/A

Regeneron Pharmaceuticals currently has a consensus price target of $826.59, suggesting a potential upside of 15.97%. Vir Biotechnology has a consensus price target of $20.25, suggesting a potential upside of 117.98%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Regeneron Pharmaceuticals beats Vir Biotechnology on 12 of the 17 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REGN vs. The Competition

Export

Metric	Regeneron Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$75.58B	$3.39B	$6.24B	$12.31B
Dividend Yield	0.53%	2.25%	2.78%	5.23%
P/E Ratio	17.37	15.06	20.87	25.70
Price / Sales	5.25	306.22	554.55	76.29
Price / Cash	17.03	56.93	27.81	36.27
Price / Book	2.41	6.94	9.77	6.74
Net Income	$4.50B	$24.11M	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	-4.82%	4.62%	6.28%	8.98%
1 Year Performance	35.05%	78.21%	41.80%	42.44%

Regeneron Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REGN Regeneron Pharmaceuticals	4.429 of 5 stars	$712.77 -0.3%	$826.59 +16.0%	+35.5%	$75.58B	$14.34B	17.37	15,410	Positive News
AMGN Amgen	4.0292 of 5 stars	$322.60 -0.4%	$357.12 +10.7%	+24.8%	$173.55B	$37.22B	22.38	31,500	Analyst Revision
GILD Gilead Sciences	4.6935 of 5 stars	$133.03 +0.3%	$157.35 +18.3%	+35.6%	$164.99B	$29.44B	19.64	17,000	Trending News Earnings Report Dividend Announcement Analyst Forecast
MRNA Moderna	1.5012 of 5 stars	$46.50 -1.7%	$35.73 -23.2%	+124.1%	$18.35B	$1.94B	N/A	4,700	Trending News Gap Up
NTLA Intellia Therapeutics	3.2087 of 5 stars	$13.40 -3.4%	$20.09 +49.9%	+73.5%	$1.58B	$67.67M	N/A	600	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REGN) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Do institutionals and insiders believe in REGN or AMGN?

Do analysts prefer REGN or AMGN?

Is REGN or AMGN a better dividend stock?

Is REGN or AMGN more profitable?

Does the media refer more to REGN or AMGN?

Which has more volatility and risk, REGN or AMGN?

Which has stronger valuation and earnings, REGN or AMGN?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Which has stronger valuation and earnings, REGN or GILD?

Do institutionals and insiders believe in REGN or GILD?

Which has more volatility and risk, REGN or GILD?

Is REGN or GILD a better dividend stock?

Does the media refer more to REGN or GILD?

Do analysts prefer REGN or GILD?

Is REGN or GILD more profitable?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Which has stronger earnings and valuation, REGN or MRNA?

Do institutionals and insiders hold more shares of REGN or MRNA?

Which has more volatility and risk, REGN or MRNA?

Does the media favor REGN or MRNA?

Do analysts recommend REGN or MRNA?

Is REGN or MRNA more profitable?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Which has stronger earnings and valuation, REGN or NTLA?

Which has more volatility and risk, REGN or NTLA?

Does the media favor REGN or NTLA?

Is REGN or NTLA more profitable?

Do analysts recommend REGN or NTLA?

Do institutionals and insiders hold more shares of REGN or NTLA?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Do insiders & institutionals have more ownership in REGN or VIR?

Does the media favor REGN or VIR?

Is REGN or VIR more profitable?

Which has more risk & volatility, REGN or VIR?

Which has better earnings and valuation, REGN or VIR?

Do analysts rate REGN or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools